A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection
Public ClinicalTrials.gov record NCT07024641. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection
Study identification
- NCT ID
- NCT07024641
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- GigaGen, Inc.
- Industry
- Enrollment
- 48 participants
Conditions and interventions
Conditions
Interventions
- GIGA-2339 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 12, 2024
- Primary completion
- Oct 31, 2028
- Completion
- Oct 31, 2028
- Last update posted
- Jul 16, 2026
2024 – 2028
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Grifols Investigative site | Chandler | Arizona | 85225 | Recruiting |
| Grifols Investigative site | Huntington Beach | California | 92647 | Recruiting |
| Grifols Investigative site | Lake Forest | California | 92630 | Recruiting |
| Grifols Investigative site | Long Beach | California | 90805 | Recruiting |
| Grifols Investigative site | Oakland | California | 94605 | Suspended |
| Grifols Investigative Site | Peachtree Corners | Georgia | 30071 | Recruiting |
| Grifols Investigative Site | Iowa City | Iowa | 52242 | Recruiting |
| Grifols Investigative Site | Lenexa | Kansas | 66219 | Recruiting |
| Grifols Investigative site | Baltimore | Maryland | 21287 | Recruiting |
| Grifols Investigative site | San Antonio | Texas | 78215 | Recruiting |
| Grifols Investigative site | Webster | Texas | 77598 | Recruiting |
| Grifols Investigative site | Richmond | Virginia | 23284 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07024641, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 16, 2026 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07024641 live on ClinicalTrials.gov.